Overview

Abiraterone acetate (brand names Zytiga, Yonsa) represents a paradigm shift in the management of advanced prostate cancer.¹ By targeting the CYP17A1 enzyme, this agent halts androgen production not only in the testes but also in the adrenal glands and tumor microenvironment, achieving "medical adrenalectomy."² This report synthesizes pivotal data from Phase III trials, safety profiles, and pharmacoeconomic strategies, highlighting abiraterone's evolution from a salvage therapy to a standard-of-care backbone for both metastatic castration-resistant (mCRPC) and castration-sensitive prostate cancer (mCSPC).

Mechanism of Action and Pharmacology

• CYP17A1 Inhibition: Abiraterone irreversibly inhibits CYP17A1, blocking the conversion of pregnenolone and progesterone into androgen precursors (DHEA and androstenedione).³ This reduces serum testosterone to <1 ng/dL.
• Mineralocorticoid Excess: The blockage of cortisol synthesis shunts the steroidogenic pathway toward mineralocorticoids. This accumulation causes hypertension, hypokalemia, and fluid retention.
• Role of Prednisone: To counteract the loss of cortisol and suppress the compensatory ACTH surge, abiraterone is co-administered with low-dose corticosteroids (prednisone or methylprednisolone).⁴

Clinical Efficacy and Indications

Metastatic Castration-Resistant Prostate Cancer (mCRPC):

• Post-Chemo (COU-AA-301): Demonstrated a 35% reduction in risk of death compared to placebo.
• Chemo-Naïve (COU-AA-302): Doubled radiographic progression-free survival (rPFS) and significantly extended overall survival, establishing it as a first-line treatment.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC):

• LATITUDE & STAMPEDE Trials: Validated "upstream intensification." Treating patients earlier with abiraterone + ADT reduced mortality risk by approximately 40% compared to ADT alone.
• Emerging Combinations: The Akeega formulation (Abiraterone + Niraparib) is now FDA-approved for BRCA-mutated mCRPC and mCSPC, utilizing synthetic lethality to target DNA repair defects.⁵

Safety Profile and Monitoring

• Cardiovascular & Metabolic: Major side effects include hypertension (22-37%), hypokalemia, and peripheral edema. Monthly monitoring of blood pressure and electrolytes is mandatory.⁶
• Hepatotoxicity: Liver function tests (LFTs) are required every two weeks for the first three months due to the risk of transaminase elevations.⁷
• Comparison to AR Antagonists: Unlike Enzalutamide or Apalutamide, abiraterone does not cross the blood-brain barrier significantly and lowers seizure risk, making it preferable for patients with neurological histories. However, it requires caution in patients with severe heart failure or uncontrolled diabetes.

Pharmacoeconomics and Dosing Strategies

The Food Effect: Abiraterone is highly lipophilic.⁸ Taking the standard dose with food increases absorption up to 10-fold, which can be toxic.

Low-Dose Strategy: Clinical studies and NCCN guidelines support an alternative regimen of 250 mg taken with a low-fat meal.⁹ This achieves comparable blood levels to the standard 1,000 mg fasting dose while reducing costs by 75%.

Generic Availability: The patent expiration of Zytiga has led to the availability of generic abiraterone, significantly reducing the financial burden on patients and healthcare systems.

FAQ

Q: Why must abiraterone be taken with prednisone?

A: Abiraterone blocks cortisol production.¹⁰ Prednisone replaces this missing physiological cortisol and prevents the pituitary gland from over-stimulating the adrenals, which would otherwise cause severe high blood pressure and low potassium.¹¹

Q: Can I eat before taking abiraterone?

A: For the standard 1,000 mg dose, you must be fasting (1 hour before or 2 hours after food) to avoid dangerous spikes in drug absorption. However, if your doctor prescribes the alternative low-dose (250 mg) strategy, it must be taken specifically with a low-fat meal.

Q: How does abiraterone differ from Enzalutamide?

A: Abiraterone stops androgen production (enzyme inhibitor) and requires steroids, whereas Enzalutamide blocks the androgen receptor and does not require steroids.¹² Abiraterone is often preferred for patients with a history of seizures or falls.

Q: Is abiraterone used for non-metastatic cancer?

A: Recent guidelines (e.g., in the UK) have approved abiraterone for high-risk non-metastatic (M0) disease based on data showing it significantly delays metastasis, moving the drug into a curative-intent setting.

Q: What foods should be avoided while on this medication?

A: Patients must strictly avoid grapefruit and Seville oranges, as they inhibit the enzymes that break down abiraterone, potentially leading to toxic drug levels in the body.¹³ A heart-healthy, low-sodium diet is also recommended to manage fluid retention.